| Private Placement / Financing Transactions
Seamless Therapeutics: The company raised $1.1 billion of venture funding from Eli Lilly on January 30, 2026. The company is a developer of a gene editing technology used to enable targeted modification of genetic material.
Hologen: The company is reportedly in the process of raising $500 million Series A of venture funding led by Averin and ATLAS INVESTMENTS on January 28, 2026. The company is a developer of multi-modal generative AI models designed to improve the understanding, design, evaluation, and delivery of treatments for neurological and complex diseases.
Cellares: The company raised $257 million of Series D venture funding in a deal led by BlackRock Private Equity Partners and Eclipse Ventures on January 28, 2026. Intuitive Ventures, Baillie Gifford, EDBI, Gates Frontier, Decheng Capital, DFJ Growth, T. Rowe Price Group, Willett Advisors and Duquesne Family Office also participated in the round. The company is an operator of an integrated development and manufacturing organization intended for accelerating patients’ access to life-saving cell therapies.
Tenpoint Therapeutics: The company raised $235 million of venture funding through a combination of debt and equity on January 28, 2026. An $85 million Series B round was led by EQT, Hillhouse Investment Group and British Business Bank with participation from Janus Henderson Investors, Eight Roads, EQT Life Sciences, F-Prime Capital, AdBio partners, Sofinnova Partners, Qiming Venture Partners USA, Wille Finance, and other undisclosed investors. The company is an operator of a biotechnology platform intended to restore vision for people with degenerative ocular diseases.
TRexBio: The company raised $134 million of Series B venture funding from Pfizer Ventures, Avego Management and SV Health Investors on January 27, 2026, putting the company’s pre-money valuation at $140.9 million. Agent Capital, Delos Capital Partners, Alexandria Venture Investments, Polaris Partners, Johnson & Johnson Innovation – JLABS, Eli Lilly and Company Foundation, Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors and other undisclosed investors also participated in the round. The company is a developer of biotechnology therapeutics designed to treat immune-mediated diseases.
Antheia: The company raised $80 million of Series C venture funding in a deal led by EDBI, Athos, Global Health Investment Corporation and America’s Frontier Fund on January 27, 2026. Echo Investment Capital, Federov, Sherpalo Ventures, Civilization Ventures, In-Q-Tel, Viking Global Investors, S-Cubed Capital and other undisclosed investors also participated in the round. The company is an operator of a synthetic biology platform that engineers yeast fermentation pathways to biosynthesize plant-derived pharmaceutical compounds.
Breakthru Medicine: The company raised $60 million of Series A venture funding from Fred Eshelman, Mark Gergen, and other undisclosed investors on January 29, 2026. The company is an operator of a biotechnology business developing small molecule and biologic oncology therapeutics targeting tumor growth and immune pathways.
Automata: The company raised $45 million of Series C venture funding in a deal led by Dimension on January 29, 2026. Danaher, Tru Arrow Partners, Entrepreneurs First, Octopus Ventures, and Murali Venkatesan also participated in the round. The company is a developer of modular robotic workcells and software that automate liquid handling, sample processing, and lab workflow operations.
Rhino: The company raised $26.3 million of Series A venture funding in a deal led by AlleyCorp on January 27, 2026. TELUS Global Ventures, Bird Capital, LionBird, Fusion Fund, Qiming Venture Partners USA, Gaingels, Mana Ventures, E12 Venture Capital, Keren Maccabi, Frank Sica and other undisclosed investors also participated in the round. The company is a developer of a federated learning and edge-computing platform that trains machine learning models across distributed data sources without centralizing raw data.
Primmune Therapeutics: The company raised $23.3 million of Series B venture funding from Oberland Capital, Bioqube Ventures and Samsara BioCapital on January 26, 2026. Other undisclosed investors also participated in the round. The company is a developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy.
Vinci Pharmaceuticals: The company raised $20.2 million of Series A venture funding from undisclosed investors on January 26, 2026, putting the company’s pre-money valuation at $22 million. The company is a developer of a retinal disease treatment platform designed to prevent blindness of people suffering from intermediate-stage diseases of the retina.
CraniUS Therapeutics: The company raised $20 million of Series B venture funding from State of Maryland on January 28, 2026. The company is a developer of implantable drug delivery devices that enable direct, sustained delivery of therapeutics across the blood-brain barrier.
Prenosis: The company raised $20 million of Series A venture funding in a deal led by PACE Healthcare Capital on January 29, 2026. Labcorp Venture Fund, The Carle Foundation, Global Health Investment Corporation, Illinois Department of Commerce and Economic Opportunity, UC Investments and UCI Health Ventures also participated in the round. The company is a developer of AI-based diagnostic software that analyzes clinical data streams to identify disease risk and progression in acute care settings.
PranaX: The company raised $17 million of Series A venture funding from undisclosed investors on January 29, 2026. The company is a developer of exosome-derived supplements formulated to support cellular signaling and regeneration processes.
Riverain Technologies: The company raised $8.2 million of venture funding from undisclosed investors on January 26, 2026. The company is a developer of medical imaging software that enhances radiographic scans using image processing algorithms to improve detection of lung disease.
Elysium Therapeutics: The company raised $7.5 million of venture funding in the form of SAFE notes from undisclosed investors on January 28, 2026. The company is a developer of opioid pain relievers designed to protect individuals from oral misuse, abuse, and fatal overdose.
28bio: The company raised $6.5 million of Series A3 venture funding from undisclosed investors on January 27, 2026. The company is a developer of a brain-on-a-chip platform designed to capture neurological processes in the brain and nervous system.
Alume Biosciences: The company raised $5.9 million of Series C venture funding from undisclosed investors on January 29, 2026. The company is a developer of fluorescent nerve imaging agents and visualization technology used during surgical procedures.
Epikast: The company raised an undisclosed amount of venture funding in a deal led by Kos Biotechnology Partners on January 30, 2026. The company is a developer of software that uses data-driven profiling to personalize digital communication between patients, providers, and caregivers.
Stellular Bio: The company raised an undisclosed amount of Series 1 venture funding in a deal led by Ziff Capital Partners on January 28, 2026. Cockrell Interests and other undisclosed investors also participated in the round. The company is a developer of a pioneering platelet-derived regenerative biologic platform designed to improve the lives of patients with ocular surface disease.
TibaRay: The company raised an undisclosed amount of venture funding from IHH Healthcare and K2X on January 29, 2026. The company is a developer of medical device technologies used in radiation and energy-based cancer treatment systems.
|
